Navigation Links
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
Date:1/17/2011

STANFORD, Calif. Researchers at the Stanford University School of Medicine, in collaboration with BioParadox, Inc., have published data supporting the use of platelet-rich plasma as a promising biologic treatment for myocardial infarction (heart attack).

The findings were published online in Cardiovascular Revascularization Medicine and will be presented at The Sixth International Conference on Cell Therapy for Cardiovascular Disease at Columbia University Medical Center, New York City, on January 20, 2011.

Platelet-rich plasma (PRP) has been identified as a novel biologic treatment for wound healing and sports-related injuries. Studies indicate PRP stimulates cell repair via growth factor release and by attracting reparative cells. Only recently, however, have scientists begun to study PRP's potential in repairing damaged cardiovascular tissue.

Working with colleagues at Stanford University Medical Center, lead author Allan Mishra, MD, a leading PRP researcher, studied the effects of RevaTen PRP (a proprietary formulation of concentrated platelets and white blood cells) on cardiac function after inducing cardiac ischemia (damage to myocardial tissue caused by blood restriction) in mice. The research was conducted under the direction of Robert Robbins, MD, chairman of the department of cardiothoracic surgery at Stanford University.

In this study of 28 mice, researchers induced ischemia by either permanently occluding the left anterior descending artery (Group A) or temporarily ligating it for 45 minutes (Group B). The hearts were then injected with RevaTen PRP or saline control. In order to assess cardiac function after treatment, magnetic resonance images were taken at seven days post-procedure (Group A) and 21 days (Group B). Tissue from all hearts was collected for histopathologic evaluation.

In both groups, mice that received PRP after ischemia had significantly better cardiac function as measured by left ventricular ejection fraction on MRI than those that had been injected with saline only. In group A, the RevaTen-treated animals had 38% better ejection fraction compared to saline controls. In group B, the RevaTen-treated animals had 28% improvement in ejection fraction compared to controls. Additionally, less scar tissue was found in RevaTen-treated hearts than in controls.

"Although this is an observational study using an animal model, PRP might someday be employed at the point of care to treat patients who have had a heart attack. This could preserve cardiac function and limit the progression to congestive heart failure," Dr. Mishra says. "Since myocardial infarction remains the leading cause of death in industrial nations, RevaTen PRP may become a powerful biologic tool in fighting heart disease and provide cost savings." The authors caution that this is a preclinical study and that further translational research is needed to understand how RevaTen PRP might work to repair and/or protect cardiovascular tissue.


'/>"/>

Contact: Patti Davis
patti@davismedpr.com
630-920-8042
DAVIS MEDPR, Inc.
Source:Eurekalert

Related biology news :

1. How Toxoplasma gondii gets noticed
2. Plasma produces KO cocktail for MRSA
3. Modeling Toxoplasma focus of workshop
4. Toxoplasma gondii spreads in the habitat of the Iberian lynx
5. Atmospheric pressure plasma jet from a grounded electrode
6. Grant advances quark-gluon plasma studies

7. Scripps Research scientists redefine the role of plasma cells in the immune system
8. MIT researchers study the danger of toxoplasma parasites
9. Long-term study shows effect of climate change on animal diversity
10. New approach to treating cystic fibrosis lung infection shows promise
11. Research shows Brazilian acai berry antioxidants absorbed by human body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)... 25, 2016   Unisys Corporation (NYSE: UIS ) ... Kennedy (JFK) International Airport, New York City , ... imposters attempting to enter the United States ... pilot testing of the system at Dulles last ... at JFK during January 2016. --> pilot testing ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... is introducing a hybrid membership model which will provide ... joining or renewing through an organizational purchasing model. For ... employee in any size association or AMC office can ... benefits.   John H. Graham, IV , ... organizations of any size and their employees to gain ...
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY ... of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, ... more than 100 tables for its annual event, which will run from 3:00 ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... registry built on the secure online PatientCrossroads platform, has exceeded both its one-year ... have joined the PROMPT study, which seeks to advance understanding of the hereditary ...
Breaking Biology Technology: